(Reuters) - The U.S. Department of Veterans Affairs said it has stopped using Roche's Avastin to treat a sight-robbing eye disease as it looks into reports of increased risk of infection. Roche's ...

WASHINGTON (AP) - Federal health authorities recommended Thursday that the drug Avastin no longer be used to treat breast cancer, saying recent studies failed to show the drug's original promise to ...

One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...

Regulators will clear a path for review of Genentech Inc.'s Avastin — one of the world's best-selling cancer drugs — as the company tries to extend the drug's use to certain types of cervical cancer.

A panel of cancer experts ruled Wednesday that Avastin - the world's best-selling cancer drug, developed by Genentech in South San Francisco - should no longer be used in breast cancer patients ...

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug ...

The National Institute for Health and Clinical Excellence (NICE) has issued final guidance not recommending the use of Roche's Avastin (bevacizumab), Merck Serono's Erbitux (cetuximab) or Amgen's ...

Avastin, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary ...

WASHINGTON, June 26 (Reuters) -- Drugmaker Roche Holding AG will try to convince U.S. regulators to reverse course on Avastin, the world's best-selling cancer medicine, and approve its use for breast ...

October 12, 2010 — Newer therapies for age-related macular degeneration (AMD), including bevacizumab and ranibizumab, do not appear to be associated with increased risk for mortality, myocardial ...